Screener
Intellia Therapeutics NTLA Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The source filing: Intellia Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337952
FAQ
- What is Intellia Therapeutics's total costs & expenses?
- Intellia Therapeutics (NTLA) reported total costs & expenses of $120.42M in Q2 2026.
- How has Intellia Therapeutics's total costs & expenses changed year-over-year?
- Intellia Therapeutics's total costs & expenses decreased by 3.1% year-over-year, from $124.24M to $120.42M.
- What is the long-term trend for Intellia Therapeutics's total costs & expenses?
- Over 4 years (2021 to 2025), Intellia Therapeutics's total costs & expenses has grown at a 14.0% compound annual growth rate (CAGR), from $300.9M to $508.66M.
- What does total costs & expenses mean?
- This metric represents the aggregate sum of all operating and non-operating costs incurred by the company during a reporting period, including research and development, general and administrative, and other operational expenditures. It serves as a primary indicator of the company's total burn rate and operational scale. Monitoring this figure is essential for assessing the efficiency of resource allocation and the sustainability of the company's current business model.
Ask your AI about Intellia Therapeutics's total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude